SurgiLance Safety Lancet Part of Major HIV Testing Initiative in Sub-Saha...(mponent of the BundiRapid HIV-1/2 Test K...),Health

Date:4/17/2008

mponent of the Bundi Rapid HIV-1/2 Test Kit and sets us apart from other HIV test kits," says Bundi president Robert Udeagha. "The SurgiLance safety lancet allows consistent depth of penetration, provides optimal blood flow in mere seconds, delivers a quality blood sample and is virtually pain-free for patients undergoing HIV testing. Best of all," says Udeagha, "the inclusion of SurgiLance safety lancets completely eliminates the dangers associated with accidental needle stick, which is one means of HIV transmission."

About MediPurpose

MediPurpose designs, manufactures and markets innovative healthcare solutions valued by its customers. The company is known for introducing quality safety medical devices that protect healthcare professionals from sharps injury. Founded in 1999, the company achieved rapid success with its SurgiLance safety lancet, quickly becoming one of the top leaders in the US safety lancet market and establishing solid distribution channels worldwide.

As a globally recognized innovator, MediPurpose has developed a menu of services to assist inventors and growing medical device companies successfully design, patent, manufacture and sell their products. MediPurpose maintains offices in the US, Singapore, the UK, France and Spain.

For more information on MediPurpose, visit http://www.medipurpose.com .

'/>"/>

SOURCE MediPurpose Copyright©2008 PR Newswire. All rights reserved

3 GOOD

Page: 1 2
Related medicine technology :

1. Cardiac Safety Study of Stinger S-200 Published
2. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
3. VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
4. EnVivo Pharmaceuticals Announces Initiation of Clinical Safety and Biomarker Study of Alpha-7 Nicotinic Agonist, EVP-6124, in Patients with Schizophrenia
5. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
6. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
7. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
8. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
9. FluoroPharma Announces Positive Phase I Safety Results for CardioPET(TM), Coronary Artery Disease (CAD) Imaging Tracer for Positron Emission Tomography (PET)
10. DATATRAK and COResearch to Collaborate on Six Cardiac Safety Projects
11. Media Statement: MHA Keystone Center for Patient Safety & Quality OHRP Ruling